logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Invasive Aspergillosis

    FiltersReset Filters
    6 results

    • cresemba

      (isavuconazonium sulfate)
      Astellas Pharma US, Inc.
      Usage: CRESEMBA is indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adults and pediatric patients. It is available as an injection for patients aged 1 year and older, and as capsules for those aged 6 years and older who weigh at least 16 kg.

    • posaconazole

      (posaconazole)
      Par Pharmaceutical Inc.
      Usage: Posaconazole is indicated for treating invasive aspergillosis in patients aged 13 and older, prophylaxis of invasive Aspergillus and Candida infections in high-risk patients, and treating oropharyngeal candidiasis, including cases resistant to itraconazole or fluconazole, in patients aged 13 and older.

    • vfend

      (voriconazole)
      Roerig
      Usage: VFEND is indicated for treating invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium and Fusarium species in patients aged 2 years and older. Testing for causative organisms should precede therapy, but treatment may begin before results are available.

    • voriconazole

      (voriconazole)
      Sandoz Inc
      Usage: Voriconazole tablets are indicated for treating invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium and Fusarium species in patients aged 2 years and older. Fungal cultures should guide therapy adjustments post-initiation.

    • voriconazole

      (voriconazole)
      Zydus Lifesciences Limited
      Usage: Voriconazole tablets are indicated for treating invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious infections caused by Scedosporium and Fusarium species in patients aged 2 years and older. Initial therapy may begin before laboratory results are available, but should be adjusted based on findings.

    • voriconazole

      (voriconazole)
      Viona Pharmaceuticals Inc
      Usage: Voriconazole tablets are indicated for treating invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium and Fusarium species in patients aged 2 years and older, particularly those intolerant or refractory to other therapies.